The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The kidney care provider has established over 40 dialysis centres, delivering more than 40,000 dialysis sessions
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
The precision health platform integrates genetics, biomarkers, diet, and lifestyle data to deliver personalised gut health interventions and therapy support
Subscribe To Our Newsletter & Stay Updated
